Outlook Therapeutics
Biotechnology Research • 
Cranbury, New Jersey, United States • 51-100 Employees
Company overview
| Headquarters | 7 Clarke Dr, Cranbury, New Jersey 08512, US |
| Phone number | +16096193990 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2011 |
| Employees | 51-100 |
| Socials |
Key Contacts at Outlook Therapeutics
Tony Moses
Executive Director Of Physician Relations
Edwin Chan
Senior Director, Drug Product Operations
Danielle Greene
Senior Director Of Talent Acquisition And Hr Strategy
Glen Olsheim
Executive Director, Commercial Excellence
Tyler Collins
Senior Director, Cmc Operations
Kathleen Billman
Executive Director, Clinical Affairs
Mediana Avdiu
Director -Commercial Gmp Quality Assurance
Pamela Monterola
Senior Director, Regulatory And Clinical Affairs
Lawrence Kenyon
Cfo And Director
Kurt J Hilzinger
Board Of Directors | Audit Chair
Outlook Therapeutics Email Formats
Outlook Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@outlooktherapeutics.com), used 72.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@outlooktherapeutics.com | 72.4% |
{first name}{last name} | johndoe@outlooktherapeutics.com | 27.6% |
About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a BLA has been resubmitted to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Outlook Therapeutics revenue & valuation
| Annual revenue | $1,505,322 |
| Revenue per employee | $29,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $4,900,000 |
| Total funding | $108,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Outlook Therapeutics has 27 employees across 11 departments.
Departments
Number of employees
Funding Data
Explore Outlook Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Outlook Therapeutics Tech Stack
Discover the technologies and tools that power Outlook Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Hosting
Video players
JavaScript libraries
JavaScript libraries
Maps
JavaScript libraries
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Israel
United Kingdom
Australia
United Arab Emirates
TürkiyeFrequently asked questions
4.8
40,000 users
